GlassScriptPhysician profile
Laurie L Carr
NPI 1346287968
$45,587.66
in general payments reported to CMS, 2019-2025
18 companies · $9,995 in 2025
The $9,995 reported for 2025 was more than what 81% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,112 · 2020: $7,776 · 2021: $12K · 2022: $2,759 · 2023: $2,055 · 2024: $3,395 · 2025: $9,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,345.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16,512.32 | 2019-2025 | Enhertu, Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $8,182.50 | 2020-2021 | |
| Beone Medicines USA, INC. | $5,775.00 | 2025 | |
| Lilly USA, LLC | $5,462.50 | 2021 | |
| Daiichi Sankyo INC. | $4,850.00 | 2024-2025 | |
| Pfizer INC. | $1,600.00 | 2022 | |
| Blueprint Medicines Corporation | $1,306.25 | 2020 | |
| Orphai Therapeutics INC. | $1,125.00 | 2022 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Genentech, INC. | $139.95 | 2019 | |
| Janssen Biotech, INC. | $99.99 | 2025 | Rybrevant |
| Celgene Corporation | $17.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.92 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.